Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1Phase 1/2 1

Status

Recruiting 3Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 5NIH 1INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 5Sarcoma 1NET 1Gynecologic 1Gastrointestinal 1Endocrine 1Breast 1

Conditions

Carcinoma, Renal Cell 3Prostatic Neoplasms 2Vulvar Neoplasms 1Sarcoma 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Neoplasm Metastasis 1Gallbladder Neoplasms 1Clear-cell metastatic renal cell carcinoma 1Carcinoma, Neuroendocrine 1Breast Neoplasms 1Bile Duct Neoplasms 1

Interventions

pembrolizumab 589Cyclophosphamide 539Magnetic Resonance Spectroscopy 523Radiotherapy 506Specimen Handling 503Nivolumab 407Cisplatin 370Carboplatin 358Biopsy 304Blood Specimen Collection 295Radiosurgery 283Paclitaxel 274Surveys and Questionnaires 268Standard of Care 266Gemcitabine 265fludarabine 261Dexamethasone 258Drug Therapy 256venetoclax 246Bevacizumab 246Oxaliplatin 206Rituximab 195Capecitabine 194Radiation 189Fluorouracil 186Ipilimumab 184durvalumab 180Doxorubicin 175atezolizumab 172Etoposide 171

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
OTHER × tivozanib × 1 year × Clear all
NCT05000294 2026-06-05

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

University of Florida

Phase 1/2 Recruiting
29 enrolled
BreastEndocrineGastrointestinalGenitourinaryGynecologicNETSarcoma

Bile Duct Neoplasms, Breast Neoplasms, Gallbladder Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Vulvar Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT06661720 2026-06-02

STRIKE

Alliance for Clinical Trials in Oncology

Phase 3 Recruiting
1,040 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT01885949 2026-05-20

Tivozanib + Enzalutamide in Adv Prostate Cancer

Massachusetts General Hospital

Phase 2 Terminated
5 enrolled 8 charts
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT06053658 2026-05-20

Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma

M.D. Anderson Cancer Center

Phase 2 Recruiting
48 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT07218692 2025-10-20

RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy

City of Hope Medical Center

Phase 2 Not yet recruiting
35 enrolled
Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡